NICE refuses the appeal for Alzheimer's drug treatments

NICE has today (Wednesday 11 October) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer's disease have not been upheld.

Test for Alzheimer's disease
Test for Alzheimer's disease

This final guidance from NICE will recommend to the NHS in November that donepezil, galantamine and rivastigmine should only be considered as options for treatment of people with moderate Alzheimer’s disease. Memantine is only recommended as part of clinical studies for people with moderate-severe to severe Alzheimer’s disease.

In 2001 NICE guidance recommended that the Alzheimer’s drugs should be used as a standard treatment. However, a further appraisal in 2005 resulted in NICE stating that the drugs should be restricted as the cost of treating these patients was not supported by the available evidence.

The pharmaceutical manufacturers were asked to present further evidence of the effectiveness of these treatments in patients with mild Alzheimer’s disease.

Andrew Dillon, NICE chief executive, said: ‘Alzheimer’s is a cruel and devastating illness and we realise that today’s announcement will be disappointing to people with Alzheimer’s disease and those who treat and care for them. But we have to be honest and say that based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough difference for us to recommend their use for treating all stages of Alzheimer’s disease.’

Pfizer and Eisai, manufacturers of donepezil, are reported to be considering a judicial review of the decision.


eMIMS links

Alzheimer's dementia

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

GPs to place orders for COVID-19 vaccine as NHS targets second dose at 12 weeks, says Stevens

GPs to place orders for COVID-19 vaccine as NHS targets second dose at 12 weeks, says Stevens

GP-led vaccination sites will be able to place orders for COVID-19 vaccine supplies...

RCGP and Marie Curie urge GPs to adopt end of life care standards for care homes

RCGP and Marie Curie urge GPs to adopt end of life care standards for care homes

Best practice standards to help GPs improve end of life care in care homes despite...

Thank your team for their inspirational work during the COVID-19 pandemic #myGPteam

Thank your team for their inspirational work during the COVID-19 pandemic #myGPteam

Never has teamwork in general practice been more important than during the COVID-19...

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

BMA mourns 'dark death toll' as UK passes 100,000 COVID-19 deaths

More than 100,000 people have now died from COVID-19 in the UK, five times the death...

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Viewpoint: End-of-life care in care homes goes well beyond COVID-19

Best practice standards for GPs and teams caring for older people in care homes -...